INCA033989, a novel mutant CALR-specific monoclonal antibody, was a hot topic in the field of MPNs at #ASH25, with promising early results in both #EssentialThrombocythemia & #Myelofibrosis.🩸

Hear more from @harrisoncn1 of @GSTTnhs:
🎥 👉

#MPNsm #HemOnc

Safety & efficacy of INCA033989, a first-in-class mutant CALR-specific mAb, in patients with ET & MF

Claire Harrison, MD, FRCP, FRCPath, Guy's and St Thomas' NHS Foundation Trust, London, UK, discusses the safety and ...

ow.ly

In an interview from #ASH25, @akshatdoctor (@LLUMedSchool) discusses real-world experience with the anti-tissue factor pathway inhibitor marstacimab in severe & non-severe #hemophilia, highlighting its potential to revolutionize treatment for patients.

Click to watch: 🎥

🗞️ In a recent paper in @Haematologica, the longest survival to date in any unselected group of patients with #MultipleMyeloma was reported (an average of almost 13 years).

🎥 We caught up with Dr James Berenson (@myelomadoc) to gain insight into the paper & to hear about the

Have you registered for #CART26 yet?🩸

Hear from @ARampotas, who highlights the importance of the meeting as a platform for exchanging ideas & showcasing new data in the field of CAR-T & cellular therapy:

🎥

Click here to register your attendance (in

The upcoming EBMT-EHA European CAR T-cell meeting 2026: sharing updates in CAR-T & cellular therapy

In this video, Alex Rampotas, MBBS, MRCP, University College London, London, UK, invites viewers to register for the...

ow.ly